Venetoclax (ABT-199), a BCL-2-specific inhibitor, has achieved clinical approval for treating BCL-2-dependent hematological malignancies, such as small lymphocytic lymphoma and chronic lymphocytic leukemia (Cory et al., 2016). This evidence concerns the gene BCL2 and hematologic disorder.